资讯
8 天
Verywell Health on MSNWho Should Get the RSV Vaccine This Year?
The CDC expanded RSV vaccine recommendations to include adults aged 50 and above who have underlying health conditions ...
2 天
Zacks Investment Research on MSNMerck Stock Down 4% Since Q2 Results: How to Play the Stock
Merck MRK stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s ...
Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...
Federal vaccine advisors on Thursday recommended Merck's new RSV antibody shot for infants younger than eight months old in their first respiratory virus season, if their mother didn't receive a ...
Merck said it expects the actions under the restructuring program to result in annual cost savings of approximately $1.7 billion, which will be substantially realized by the end of 2027.
Learn about July 2025’s top biotech deals, featuring major collaborations in small molecules, antibodies, and drug delivery.
Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing a phase 1 vaccine candidate to expand its RSV pipeline beyond mRNA.
Perhaps the most critical aspect of Moderna's business to pay attention to right now is its late-stage pipeline. The company ...
Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...
Merck said on Tuesday it was extending its pause on Gardasil shipments to China until at least the end of 2025 due to persistent weakness in demand for the blockbuster human papillomavirus vaccine ...
A new antibody shot that protects babies against RSV infection could be struggling to gain traction, researchers report.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果